Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics Inc. reported that Executive Chair Marvin L. White exercised and settled restricted stock units into common stock in July and August 2026. On August 6, 2026, 1,666 RSUs granted on August 6, 2025 converted into common shares, with 406 shares withheld at $4.07 per share to satisfy tax withholding obligations. On July 17, 2026, 1 RSU from a July 17, 2024 grant vested and converted into one common share.
Aptevo Therapeutics Inc. director Daniel Abdun-Nabi reported an exercise of equity awards. On August 6, 2026, 400 Restricted Stock Units converted into 400 shares of Common Stock on a one-for-one basis. The RSU position was reduced by 400 units to zero, and direct ownership of common stock increased to 400 shares following the transaction.
Aptevo Therapeutics Inc. director Barbara Lopez Kunz reported the vesting and conversion of 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. These 400 RSUs were part of a grant of 7,200 RSUs (400 post-split) awarded on August 6, 2025, which vested on the first anniversary of the grant date.
Aptevo Therapeutics Inc. director John Niederhuber reported the vesting and conversion of 400 Restricted Stock Units into 400 shares of common stock on August 6, 2026. The RSUs converted on a one-for-one basis into common stock. The related footnote states that on August 6, 2025, he was granted 7,200 (400 post-split) RSUs that vest on the first anniversary of the grant date.
Aptevo Therapeutics Inc. is asking stockholders to vote at a virtual annual meeting on August 21, 2026 on four key items. Stockholders will elect two directors, Zsolt Harsanyi and Barbara Lopez Kunz, to serve until the 2029 annual meeting, and vote on ratifying Baker Tilly US, LLP as independent auditor for 2026.
Investors will also cast a non-binding advisory "say‑on‑pay" vote on executive compensation for 2025 and consider approving the Fourth Amended and Restated 2018 Stock Incentive Plan, which would add 145,000 shares (market value $633,650 as of July 23, 2026) to the equity pool, on top of 7,360 shares remaining. There were 1,517,945 shares of common stock outstanding as of the July 23, 2026 record date.
The Board reports that 71% of directors are independent and all Audit, Compensation, and Nominating and Corporate Governance committee members are independent. The refreshed stock plan includes features such as no option repricing without stockholder approval, minimum one‑year vesting (with limited exceptions), a $1,000,000 annual cap on non‑employee director compensation, and clawback provisions tied to company policies and applicable law.
Aptevo Therapeutics Inc. reported a new solid tumor strategy built around a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. Announced on July 27, 2026, this backbone is designed to strengthen its oncology pipeline and expand partnering opportunities.
The backbone is intended to recognize Nectin-4 on tumors and PD-L1 on tumor and immune-suppressive cells, supporting radiopharmaceuticals, T-cell engagers and other immune-modulating therapies that combine tumor targeting, immune activation and payload delivery. Aptevo highlights that this approach leverages its ADAPTIR and ADAPTIR-FLEX platforms, complements its lead AML candidate mipletamig, and aligns with preclinical work on APVO451 and radiopharmaceutical therapeutics.
Aptevo Therapeutics Inc. entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund, under which CARE will reimburse up to $1,499,951 of eligible costs to support IND‑enabling studies for APVO451, Aptevo’s trispecific antibody candidate for solid tumors. The project is expected to run through June 2028, with payments tied to milestones, reporting obligations, and an approved budget, and requires Aptevo to provide at least matching non‑state contributions. Aptevo retains intellectual property generated under the project, subject to commercialization and public‑benefit commitments, and highlighted in a press release that the award is non‑dilutive and strategically supports advancement of its nectin‑4‑targeted trispecific immunotherapy platform.
Niowave, Inc. reported beneficial ownership of 151,723 shares of Aptevo Therapeutics Inc. common stock, representing 12.18% of the class based on 1,246,105 shares outstanding as of May 13, 2026. The filing is a Schedule 13G signed June 22, 2026, and states the position was not acquired to change or influence control.
NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc., filed an initial ownership report on Form 3. The filing shows direct ownership of 98,522 shares of Common Stock. It also lists a warrant to buy 53,201 shares of Common Stock at an exercise price of $8.00 per share, expiring on May 25, 2031.